Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years

A personalized vaccine is a powerful therapy to prevent recurrence among certain follicular lymphoma patients, according to the latest results. When these patients -- whose tumors are marked by a specific protein that may be present in up to half of people with this type of cancer -- receive a vaccine made from their own tumor cells, disease-free survival is improved by nearly two years, compared with patients who receive a placebo.

Read the whole article on Science Daily

More from Science Daily